Last updated: May 26, 2026
Journavx is an FDA-approved prescription opioid analgesic. Supplier mapping typically depends on (1) the specific marketed dosage form and strength, and (2) the manufacturing site(s) listed on the product’s FDA labeling and applicable Drug Master Files (DMFs). With only the product name provided, a complete, accurate supplier roster across finished-dose manufacturing, active pharmaceutical ingredient (API) sourcing, and key excipient supply cannot be produced without risking omission or misattribution.
Who are the finished-dose and API suppliers for Journavx?
Direct answer: A definitive supplier list for Journavx requires the product’s FDA manufacturing and labeling information for each dosage strength and the API/excipient DMF and registration data tied to the same NDA/BLA.
What supplier types exist in Journavx supply chains?
- Finished-dose manufacturers (tablet/capsule liquid fill-finish, depending on dosage form)
- API suppliers (synthetic or fermentation-derived active)
- Key intermediate suppliers (if disclosed in regulatory submissions or DMF referencing)
- Excipients and packaging suppliers (commonly covered by DMFs and/or validated supplier qualification records)
What records typically identify Journavx suppliers?
- FDA labeling “Manufactured for/Distributed by” and “Revised: Month Year” sections
- Orange Book “Manufacturing Site” fields tied to the NDA
- FDA DMF holder names and contact addresses for API and key excipients
- FFD/packing list and UDI labeling information for specific national drug codes (NDCs)
- Contract manufacturing arrangement disclosures in public court filings or consent decrees (when relevant)
How does Journavx sourcing work across dosage forms and strengths?
Direct answer: Supplier attribution is frequently strength-specific because different strengths can be produced at different sites and sometimes use different supplier lots of API/excipients.
Why strength-specific mapping matters
- Different tablet/capsule strengths often use different granulation, compression blends, or coating systems
- Packaging configurations (bottles, blister packs) change labeler and sometimes fill-finish vendors
- API lots can vary by supplier or polymorph control strategy even when the API is the same chemical entity
Which supply-chain levers affect supplier switching risk?
- DMF transferability and eligibility for direct referencing
- Analytical method transfer readiness for new sites
- Stability and bioequivalence constraints if formulation changes
- Regulatory comparability expectations if API sourcing changes
What FDA filings reveal Journavx contract manufacturers and material suppliers?
Direct answer: Supplier names are most reliably confirmed through the NDA’s manufacturing/labeling disclosures and any DMFs cited in the submission.
Orange Book vs. DMFs: what each covers
- Orange Book: identifies drug product details and can include manufacturing site identifiers for marketed products
- DMFs: identify API/excipient manufacturing and the DMF holders, which may not match the labeler
What to extract for a defensible supplier dossier
- NDA number and product code
- NDC-level mapping to manufacturing site(s)
- DMF numbers for API and key excipients plus DMF holder
- Change history if the product lists “Manufactured at” changes over time
Which companies are likely suppliers to Journavx’s US launch supply?
Direct answer: Without the NDA/BLA number, NDCs, and dosage form specifics, naming specific companies would be speculative.
Supplier categories that may appear in public sources
- Labeler and marketing authorization holder
- Primary contract manufacturing organization (CMO) for finished dose
- API manufacturer(s) with DMFs referenced to the NDA
- Co-packers for packaging and distribution
What generic entry risks affect Journavx supply and sourcing?
Direct answer: Generic entry typically increases price pressure and can shift sourcing, but company-level effects depend on which Orange Book patents and exclusivities are in force, and whether generics are authorized via AB-rated approvals.
How supplier switching intersects with generic competition
- Expanded sourcing can reduce supply disruption risk
- But method transfer and validation timelines slow rapid multi-sourcing
- If a new supplier uses a different polymorph or particle size distribution, release testing changes
What formulation or method patents can constrain supplier substitution for Journavx?
Direct answer: Formulation constraints typically impact excipient and process choices; method patents can limit manufacturing changes. Supplier substitution is still possible but must keep the product within approved specifications.
Common constraints that affect sourcing
- Specific coating systems and dissolution targets
- Manufacturing process steps tied to controlled release or stability
- Impurities and residual solvent limits that are supplier-sensitive
How to build a compliant supplier list for Journavx (finished dose, API, excipients)
Direct answer: A compliant and litigation-ready supplier list is built by linking:
- NDA product entries (Orange Book) to manufacturing sites,
- NDA labeling “manufactured for” data to the commercial labeler,
- referenced DMFs to API/excipient DMF holders, and
- NDC-level packaging/labeler codes to the distribution network.
Deliverables a buyer/investor typically needs
- Finished-dose manufacturing: site address, company, and which NDC(s) it covers
- API supply: DMF holder name(s), DMF number(s), and which NDC(s) reference the API
- Excipients: DMF holder(s) for critical excipients (if referenced) and the functional role
- Change log: manufacturing site or DMF updates over time
Key Takeaways
- A complete supplier roster for Journavx must be grounded in NDA/NDC-level FDA listings and DMF referencing.
- Supplier attribution is often strength-specific and can differ across finished-dose, API, and excipients.
- Without the NDA number, dosage form/strength, and NDCs, any named supplier list would be unreliable.
FAQs
- How can I confirm the finished-dose manufacturer for Journavx from FDA records?
- Do Journavx API suppliers have DMFs on file with the FDA, and how are they identified?
- Are Journavx suppliers different for each NDC or strength?
- What evidence is used to support a supplier change in FDA inspections for opioid analgesics?
- How do Orange Book exclusivities influence who supplies Journavx during generic ramp-up?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
- FDA. Drugs@FDA. (Accessed via Drugs@FDA database).
- FDA. Drug Master File (DMF) Information. (Accessed via FDA DMF listings/resources).
